{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:07:48Z","timestamp":1772842068987,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Austrian Research Fund","award":["SFB35"],"award-info":[{"award-number":["SFB35"]}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"crossref","award":["PD-041\/2015"],"award-info":[{"award-number":["PD-041\/2015"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"crossref","award":["Momentum LP-2010-003\/2015"],"award-info":[{"award-number":["Momentum LP-2010-003\/2015"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"crossref","award":["PD124467"],"award-info":[{"award-number":["PD124467"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"crossref","award":["K115698"],"award-info":[{"award-number":["K115698"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["260572"],"award-info":[{"award-number":["260572"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Molecular descriptor (2D) and three dimensional (3D) shape based similarity methods are widely used in ligand based virtual drug design. In the present study pairwise structure comparisons among a set of 4858 DTP compounds tested in the NCI60 tumor cell line anticancer drug screen were computed using chemical hashed fingerprints and 3D molecule shapes to calculate 2D and 3D similarities, respectively. Additionally, pairwise biological activity similarities were calculated by correlating the 60 element vectors of pGI50 values corresponding to the cytotoxicity of the compounds across the NCI60 panel. Subsequently, we compared the power of 2D and 3D structural similarity metrics to predict the toxicity pattern of compounds. We found that while the positive predictive value and sensitivity of 3D and molecular descriptor based approaches to predict biological activity are similar, a subset of molecule pairs yielded contradictory results. By simultaneously requiring similarity of biological activities and 3D shapes, and dissimilarity of molecular descriptor based comparisons, we identify pairs of scaffold hopping candidates displaying characteristic core structural changes such as heteroatom\/heterocycle change and ring closure. Attempts to discover scaffold hopping candidates of mitoxantrone recovered known Topoisomerase II (Top2) inhibitors, and also predicted new, previously unknown chemotypes possessing in vitro Top2 inhibitory activity.<\/jats:p>","DOI":"10.1186\/s13321-019-0390-3","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T13:02:47Z","timestamp":1573304567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Identifying new topoisomerase II poison scaffolds by combining publicly available toxicity data and 2D\/3D-based virtual screening"],"prefix":"10.1186","volume":"11","author":[{"given":"Anna","family":"Lovrics","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika F. S.","family":"Pape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1niel","family":"Szisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Kal\u00e1szi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Heffeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"Magyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9311-7827","authenticated-orcid":false,"given":"Gergely","family":"Szak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,9]]},"reference":[{"issue":"1","key":"390_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","volume":"16","author":"P Seshacharyulu","year":"2012","unstructured":"Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK (2012) Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Tar 16(1):15\u201331","journal-title":"Expert Opin Ther Tar"},{"issue":"4","key":"390_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/clpt.2012.236","volume":"93","author":"D Swinney","year":"2013","unstructured":"Swinney D (2013) Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther 93(4):299\u2013301","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"390_CR3","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd4366","volume":"13","author":"JG Moffat","year":"2014","unstructured":"Moffat JG, Rudolph J, Bailey D (2014) Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov 13(8):588\u2013602","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"390_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1208\/s12248-012-9322-0","volume":"14","author":"T Cheng","year":"2012","unstructured":"Cheng T, Li Q, Zhou Z, Wang Y, Bryant SH (2012) Structure-based virtual screening for drug discovery: a problem-centric review. AAPS J 14(1):133\u2013141","journal-title":"AAPS J"},{"issue":"2","key":"390_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1021\/ci900419k","volume":"50","author":"H Geppert","year":"2010","unstructured":"Geppert H, Vogt M, Bajorath J (2010) Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation. J Chem Inf Model 50(2):205\u2013216","journal-title":"J Chem Inf Model"},{"issue":"4","key":"390_CR6","first-page":"559","volume":"11","author":"U Rester","year":"2008","unstructured":"Rester U (2008) From virtuality to reality-virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Devel 11(4):559\u2013568","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"10","key":"390_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6(10):813\u2013823","journal-title":"Nat Rev Cancer"},{"issue":"5298","key":"390_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.275.5298.343","volume":"275","author":"JN Weinstein","year":"1997","unstructured":"Weinstein JN, Myers TG, O\u2019connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, vanOsdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RED, K P (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275(5298):343\u2013349","journal-title":"Science"},{"issue":"14","key":"390_CR9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/jnci\/81.14.1088","volume":"81","author":"KD Paull","year":"1989","unstructured":"Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81(14):1088\u20131092. \nhttps:\/\/doi.org\/10.1093\/jnci\/81.14.1088","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"390_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1021\/jm010385b","volume":"45","author":"AA Rabow","year":"2002","unstructured":"Rabow AA, Shoemaker RH, Sausville EA, Covell DG (2002) Mining the National Cancer Institute\u2019s Tumor-Screening Database: identification of compounds with similar cellular activities. J Med Chem 45(4):818\u2013840. \nhttps:\/\/doi.org\/10.1021\/jm010385b","journal-title":"J Med Chem"},{"issue":"10","key":"390_CR11","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1158\/1535-7163.MCT-05-0224","volume":"4","author":"A Wallqvist","year":"2005","unstructured":"Wallqvist A, Huang R, Covell DG, Roschke AV, Gelhaus KS, Kirsch IR (2005) Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol Cancer Ther 4(10):1559\u20131568. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-05-0224","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"390_CR12","first-page":"79","volume":"15","author":"O Keskin","year":"2000","unstructured":"Keskin O, Bahar I, Jernigan R, Beutler J, Shoemaker R, Sausville E, Covell D (2000) Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure. Anticancer Drug Des 15(2):79\u201398","journal-title":"Anticancer Drug Des"},{"issue":"2","key":"390_CR13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/ci0101049","volume":"42","author":"P Blower","year":"2002","unstructured":"Blower P, Fligner M, Verducci J, Bjoraker J (2002) On combining recursive partitioning and simulated annealing to detect groups of biologically active compounds. J Chem Inf Comput Sci 42(2):393\u2013404. \nhttps:\/\/doi.org\/10.1021\/ci0101049","journal-title":"J Chem Inf Comput Sci"},{"issue":"3","key":"390_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1021\/ci970437z","volume":"38","author":"DR Flower","year":"1998","unstructured":"Flower DR (1998) On the properties of bit string-based measures of chemical similarity. J Chem Inf Comput Sci 38(3):379\u2013386","journal-title":"J Chem Inf Comput Sci"},{"issue":"5","key":"390_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50(5):742\u2013754","journal-title":"J Chem Inf Model"},{"issue":"10","key":"390_CR16","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1021\/jm900818s","volume":"53","author":"A Nicholls","year":"2010","unstructured":"Nicholls A, McGaughey GB, Sheridan RP, Good AC, Warren G, Mathieu M, Muchmore SW, Brown SP, Grant JA, Haigh JA, Nevins N, Jain AN, Kelley B (2010) Molecular shape and medicinal chemistry: a perspective. J Med Chem 53(10):3862\u20133886. \nhttps:\/\/doi.org\/10.1021\/jm900818s","journal-title":"J Med Chem"},{"issue":"5","key":"390_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1021\/jm040163o","volume":"48","author":"TS Rush","year":"2005","unstructured":"Rush TS, Grant JA, Mosyak L, Nicholls A (2005) A shape-based 3-d scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48(5):1489\u20131495. \nhttps:\/\/doi.org\/10.1021\/jm040163o","journal-title":"J Med Chem"},{"issue":"1","key":"390_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1021\/ci0501544","volume":"46","author":"A Wallqvist","year":"2006","unstructured":"Wallqvist A, Huang R, Thanki N, Covell DG (2006) Evaluating chemical structure similarity as an indicator of cellular growth inhibition. J Chem Inf Model 46(1):430\u2013437. \nhttps:\/\/doi.org\/10.1021\/ci0501544","journal-title":"J Chem Inf Model"},{"issue":"7\u20138","key":"390_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.drudis.2011.10.024","volume":"17","author":"H Sun","year":"2012","unstructured":"Sun H, Tawa G, Wallqvist A (2012) Classification of scaffold-hopping approaches. Drug Discov Today 17(7\u20138):310\u2013324. \nhttps:\/\/doi.org\/10.1016\/j.drudis.2011.10.024","journal-title":"Drug Discov Today"},{"issue":"4","key":"390_CR20","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1021\/acs.jmedchem.6b01437","volume":"60","author":"Y Hu","year":"2016","unstructured":"Hu Y, Stumpfe D, Bajorath J (2016) Recent advances in scaffold hopping: miniperspective. J Med Chem 60(4):1238\u20131246","journal-title":"J Med Chem"},{"issue":"5","key":"390_CR21","first-page":"772","volume":"49","author":"A Skladanowski","year":"1996","unstructured":"Skladanowski A, Plisov SY, Konopa J, Larsen AK (1996) Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49(5):772\u2013780","journal-title":"Mol Pharmacol"},{"issue":"3","key":"390_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1124\/mol.58.3.649","volume":"58","author":"A Adams","year":"2000","unstructured":"Adams A, Guss JM, Collyer CA, Denny WA, Prakash AS, Wakelin LP (2000) Acridinecarboxamide topoisomerase poisons: structural and kinetic studies of the DNA complexes of 5-substituted 9-amino-(N-(2-dimethylamino) ethyl) acridine-4-carboxamides. Mol Pharmacol 58(3):649\u2013658","journal-title":"Mol Pharmacol"},{"issue":"6041","key":"390_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1126\/science.1204117","volume":"333","author":"C-C Wu","year":"2011","unstructured":"Wu C-C, Li T-K, Farh L, Lin L-Y, Lin T-S, Yu Y-J, Yen T-J, Chiang C-W, Chan N-L (2011) Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333(6041):459\u2013462","journal-title":"Science"},{"issue":"22","key":"390_CR24","doi-asserted-by":"publisher","first-page":"10630","DOI":"10.1093\/nar\/gkt828","volume":"41","author":"C-C Wu","year":"2013","unstructured":"Wu C-C, Li Y-C, Wang Y-R, Li T-K, Chan N-L (2013) On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Res 41(22):10630\u201310640. \nhttps:\/\/doi.org\/10.1093\/nar\/gkt828","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"390_CR25","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1021\/ci060056y","volume":"46","author":"H Liang","year":"2006","unstructured":"Liang H, Wu X, Guziec LJ, Guziec FS, Larson KK, Lang J, Yalowich JC, Hasinoff BB (2006) A structure-based 3d-qsar study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model 46(4):1827\u20131835","journal-title":"J Chem Inf Model"},{"issue":"4","key":"390_CR26","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1021\/ci700052x","volume":"47","author":"GB McGaughey","year":"2007","unstructured":"McGaughey GB, Sheridan RP, Bayly CI, Culberson JC, Kreatsoulas C, Lindsley S, Maiorov V, Truchon J-F, Cornell WD (2007) Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model 47(4):1504\u20131519. \nhttps:\/\/doi.org\/10.1021\/ci700052x","journal-title":"J Chem Inf Model"},{"issue":"12","key":"390_CR27","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1021\/ci100263p","volume":"50","author":"V Venkatraman","year":"2010","unstructured":"Venkatraman V, Pe\u00e9rez-Nueno VI, Mavridis L, Ritchie DW (2010) Comprehensive comparison of ligand-based virtual screening tools against the DUD data set reveals limitations of current 3D methods. J Chem Inf Model 50(12):2079\u20132093. \nhttps:\/\/doi.org\/10.1021\/ci100263p","journal-title":"J Chem Inf Model"},{"issue":"6","key":"390_CR28","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1021\/ci900507g","volume":"50","author":"D Giganti","year":"2010","unstructured":"Giganti D, Guillemain H, Spadoni J-L, Nilges M, Zagury J-F, Montes M (2010) Comparative evaluation of 3D virtual ligand screening methods: impact of the molecular alignment on enrichment. J Chem Inf Model 50(6):992\u20131004. \nhttps:\/\/doi.org\/10.1021\/ci900507g","journal-title":"J Chem Inf Model"},{"issue":"4","key":"390_CR29","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1021\/ci400620f","volume":"54","author":"A Kal\u00e1szi","year":"2014","unstructured":"Kal\u00e1szi A, Szisz D, Imre G, Polg\u00e1r T (2014) Screen3D: a novel fully flexible high-throughput shape-similarity search method. J Chem Inf Model 54(4):1036\u20131049. \nhttps:\/\/doi.org\/10.1021\/ci400620f","journal-title":"J Chem Inf Model"},{"issue":"2","key":"390_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2004.06.026","volume":"6","author":"G Szak\u00e1cs","year":"2004","unstructured":"Szak\u00e1cs G, Annereau J-P, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6(2):129\u2013137","journal-title":"Cancer Cell"},{"issue":"2","key":"390_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nrd4163","volume":"13","author":"AL Hopkins","year":"2014","unstructured":"Hopkins AL, Keser\u00fc GM, Leeson PD, Rees DC, Reynolds CH (2014) The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov 13(2):105\u2013121","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"390_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s42004-018-0043-x","volume":"1","author":"F Grisoni","year":"2018","unstructured":"Grisoni F, Merk D, Consonni V, Hiss JA, Tagliabue SG, Todeschini R, Schneider G (2018) Scaffold hopping from natural products to synthetic mimetics by holistic molecular similarity. Commun Chem 1(1):44","journal-title":"Commun Chem"},{"issue":"10","key":"390_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc1977","volume":"6","author":"Y Pommier","year":"2006","unstructured":"Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6(10):789","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"390_CR34","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1021\/jm100991m","volume":"54","author":"HYK Kaan","year":"2011","unstructured":"Kaan HYK, Weiss J, Menger D, Ulaganathan V, Tkocz K, Laggner C, Popowycz F, Joseph B, Kozielski F (2011) Structure\u2013activity relationship and multidrug resistance study of new S-trityl-l-cysteine derivatives as inhibitors of Eg5. J Med Chem 54(6):1576\u20131586","journal-title":"J Med Chem"},{"issue":"5795","key":"390_CR35","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet J-P, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929\u20131935","journal-title":"Science"},{"issue":"5886","key":"390_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.1158140","volume":"321","author":"M Campillos","year":"2008","unstructured":"Campillos M, Kuhn M, Gavin A-C, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321(5886):263\u2013266. \nhttps:\/\/doi.org\/10.1126\/science.1158140","journal-title":"Science"},{"issue":"1","key":"390_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/msb.2009.98","volume":"6","author":"M Kuhn","year":"2010","unstructured":"Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6(1):343","journal-title":"Mol Syst Biol"},{"issue":"6180","key":"390_CR38","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.1250217","volume":"344","author":"AY Lee","year":"2014","unstructured":"Lee AY, St.Onge RP, Proctor MJ, Wallace IM, Nile AH, Spagnuolo PA, Jitkova Y, Gronda M, Wu Y, Kim MK, Cheung-Ong K, Torres NP, Spear ED, Han MKL, Schlecht U, Suresh S, Duby G, Heisler LE, Surendra A, Fung E, Urbanus ML, Gebbia M, Lissina E, Miranda M, Chiang JH, Aparicio AM, Zeghouf M, Davis RW, Cherfils J, Boutry M, Kaiser CA, Cummins CL, Trimble WS, Brown GW, Schimmer AD, Bankaitis VA, Nislow C, Bader GD, Giaever G (2014) Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science 344(6180):208\u2013211","journal-title":"Science"},{"key":"390_CR39","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1021\/acs.jcim.8b00532","volume":"58","author":"H Yang","year":"2018","unstructured":"Yang H, Sun L, Wang Z, Li W, Liu G, Tang Y (2018) Admetopt: a web server for admet optimization in drug design via scaffold hopping. J Chem Inf Model 58:2051\u20132056","journal-title":"J Chem Inf Model"},{"key":"390_CR40","unstructured":"screenmd (2014) ChemAxon Ltd., JChem6.3. \nhttp:\/\/www.chemaxon.com"},{"key":"390_CR41","unstructured":"screen3d (2014) ChemAxon Ltd., JChem6.3. \nhttp:\/\/www.chemaxon.com"},{"issue":"25","key":"390_CR42","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1021\/jm049654z","volume":"47","author":"JL Jenkins","year":"2004","unstructured":"Jenkins JL, Glick M, Davies JW (2004) A 3d similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. J Med Chem 47(25):6144\u20136159","journal-title":"J Med Chem"},{"issue":"5","key":"390_CR43","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1021\/jm050468i","volume":"49","author":"Q Zhang","year":"2006","unstructured":"Zhang Q, Muegge I (2006) Scaffold hopping through virtual screening using 2d and 3d similarity descriptors: ranking, voting, and consensus scoring. J Med Chem 49(5):1536\u20131548","journal-title":"J Med Chem"},{"issue":"7","key":"390_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1021\/ci100176x","volume":"50","author":"D Fourches","year":"2010","unstructured":"Fourches D, Muratov E, Tropsha A (2010) Trust, but verify: on the importance of chemical structure curation in cheminformatics and qsar modeling research. J Chem Inf Model 50(7):1189\u20131204","journal-title":"J Chem Inf Model"},{"issue":"7","key":"390_CR45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1021\/acs.jcim.6b00129","volume":"56","author":"D Fourches","year":"2016","unstructured":"Fourches D, Muratov E, Tropsha A (2016) Trust, but verify II: a practical guide to chemogenomics data curation. J Chem Inf Model 56(7):1243\u20131252","journal-title":"J Chem Inf Model"},{"issue":"3","key":"390_CR46","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1158\/1535-7163.MCT-06-0650","volume":"6","author":"UT Shankavaram","year":"2007","unstructured":"Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6(3):820\u2013832. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0650","journal-title":"Mol Cancer Ther"},{"issue":"14","key":"390_CR47","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y (2012) Cell miner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 72(14):3499\u20133511. \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1370","journal-title":"Cancer Res"},{"key":"390_CR48","unstructured":"standardizer (2014) ChemAxon Ltd., JChem6.3. \nhttp:\/\/www.chemaxon.com"},{"key":"390_CR49","unstructured":"structurechecker (2014) ChemAxon Ltd., JChem6.3. \nhttp:\/\/www.chemaxon.com"},{"key":"390_CR50","unstructured":"Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, Stahl MT. OMEGA 2.5.1.4. OpenEye Scientific Software, Santa Fe, NM. \nhttp:\/\/www.eyesopen.com"},{"key":"390_CR51","unstructured":"Instant JChem (2014) ChemAxon Ltd., Instant JChem6.3. \nhttp:\/\/www.chemaxon.com"},{"issue":"1","key":"390_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1021\/jm0603365","volume":"50","author":"PC Hawkins","year":"2007","unstructured":"Hawkins PC, Skillman AG, Nicholls A (2007) Comparison of shape-matching and docking as virtual screening tools. J Med Chem 50(1):74\u201382","journal-title":"J Med Chem"},{"key":"390_CR53","unstructured":"ROCS 3.2.0.4. OpenEye Scientific Software, Santa Fe, NM. \nhttp:\/\/www.eyesopen.com"},{"issue":"4","key":"390_CR54","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1021\/ci100031x","volume":"50","author":"PC Hawkins","year":"2010","unstructured":"Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT (2010) Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 50(4):572\u2013584","journal-title":"J Chem Inf Model"},{"issue":"1","key":"390_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28(1):235\u2013242","journal-title":"Nucleic Acids Res"},{"key":"390_CR56","unstructured":"Small-Molecule Drug Discovery Suite 2017-1: Glide (2017) version 6.4. Schr\u00f6dinger, LLC, New York"},{"issue":"14","key":"390_CR57","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1021\/jm300687e","volume":"55","author":"MM Mysinger","year":"2012","unstructured":"Mysinger MM, Carchia M, Irwin JJ, Shoichet BK (2012) Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 55(14):6582\u20136594","journal-title":"J Med Chem"},{"issue":"9","key":"390_CR58","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/mnfr.200800571","volume":"53","author":"R Dornetshuber","year":"2009","unstructured":"Dornetshuber R, Heffeter P, Lemmens-Gruber R, Elbling L, Marko D, Micksche M, Berger W (2009) Oxidative stress and DNA interactions are not involved in Enniatin- and Beauvericin-mediated apoptosis induction. Mol Nutr Food Res 53(9):1112\u20131122","journal-title":"Mol Nutr Food Res"},{"issue":"5081","key":"390_CR59","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1126\/science.1411538","volume":"258","author":"JN Weinstein","year":"1992","unstructured":"Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJD, K P (1992) Neural computing in cancer drug development: predicting mechanism of action. Science 258(5081):447\u2013451. \nhttps:\/\/doi.org\/10.1126\/science.1411538","journal-title":"Science"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-019-0390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13321-019-0390-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-019-0390-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:22:55Z","timestamp":1604794975000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/s13321-019-0390-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,9]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s13321-019-0390-3","relation":{},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,9]]},"assertion":[{"value":"29 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}